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ABSTRACT 
Cyclophosphamide (CLP), a cytotoxic alkylating agent with immunosuppressive and antitumor properties is used in the treatment 
of different types of cancers, but it is known to cause toxicity-induced changes to the body tissues. Melatonin, an antioxidant 
mainly secreted by the pineal gland has protective properties especially against tissue toxicity. This study was aimed at 
investigating the role of melatonin (MLT) in cyclophosphamide-induced toxicity of the liver and kidney using serum biochemical 
analysis and histopathology in adult Wistar rats. Twenty-four adult male Wistar rats were grouped into four (n=6): group 1 was 
injected intraperitoneally with 0.2mL of normal saline for 14 days, group 2 was injected with 10mg/kg of melatonin 
intraperitoneally for 14 days, group 3 was injected intraperitoneally with 0.2mL of normal saline for 14 days and 150mg/kg of 
CLP on the 15th day and in group 4, the rats were injected with 10mg/kg of melatonin for 14 days and 150mg/kg of CLP on the 
15th day. Forty-eight hours after the last treatment, the rats were weighed; blood samples collected for biochemical analysis while 
liver and kidney samples were processed for histology. The results revealed that CLP-treated rats had hypokalemia and 
hypochloremia with a significant increase in the levels of liver and kidney function markers. Histopathological analysis showed 
congested central vein and widened sinusoids in the liver, while there were widened as well as congested urinary spaces and loop 
of Henle, with loss of glomerular epithelia in the kidneys. The rats treated with melatonin and CLP showed improvement in body 
weight, biochemical parameters of hepatic and renal functions as well as improved tissue conditions. In conclusion, a pre-
treatment with melatonin is recommended in cyclophosphamide therapy. 
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Cancer treatment as well as management is currently 
witnessing a number of aggressive chemotherapy and 
radiotherapy; however, chemotherapy for cancer is not 
specific for tissues, hence both normal and cancerous tissues 
are being damaged (Christina, 2008; Abdel-Hafez et al., 
2017). Cyclophosphamide (CLP), a cytotoxic alkylating bi-
functional synthetic agent belonging to nitrogen mustard 
class, is a common anticancer or anti-tumour 
chemotherapeutic agent, which works mainly by suppressing 
the immune system. CLP is commonly used in the treatment 
of lymphoma, multiple myeloma, leukaemia, ovarian cancer, 
breast cancer, small cell lung cancer, neuroblastoma and 
sarcoma. CLP has been demonstrated to be carcinogenic 
thereby increasing the possibilities of developing a number of 
cancers including lymphomas, leukaemia, skin cancer, 
transitional cell carcinoma of the bladder or other 
malignancies (Bernatsky and Clarke, 2008; Sakr et al., 2017).  
Cyclophosphamide toxicity has been reported for the liver (Li 
et al., 2010), kidney (Sakr et al., 2017) and testis (Turner and 
Lysiak, 2008; Turk et al., 2010). Some studies have shown 
that intraperitoneal administration of cyclophosphamide in 
rats could result in severe tissue oxidative stress (Bhatia et al., 
 
www.ajbrui.org 
Cyclophosphamide toxicity in liver and kidney 
408 Afr. J. Biomed. Res. Vol. 23, No.3 (September) 2020  Olukole  et al 
2006; Abdel-Hafez et al., 2017), and massive cellular damage 
(Hanaa et al., 2010), triggering apoptosis (Napolitano and 
Singh, 2002), which leads to the eventual death of normal and 
cancerous cells (Stankiewicz et al., 2002; Abdel-Hafez et al., 
2017).  Melatonin (N-acetyl-5-methoxytryptamine), secreted 
by the pineal gland in humans and animals, is the hormone 
responsible for the regulation of sleep and wakefulness 
(Olukole et al., 2018). Melatonin (MLT) is also secreted by 
some other tissues apart from the pineal gland, including the 
liver, skin and small intestine (Hardeland et al., 1995; Rocha 
et al., 2015). In mammals, the highest circulating levels of 
MLT in blood has been demonstrated during sleep, especially 
that a number of sleep and mood disorders including jet lag 
and shift workers’ conditions have been traced to 
disequilibrium of MLT secretion and/or production (Lam et 
al., 1990; Arendt et al., 1997; Rocha et al., 2015). MLT is also 
produced in plants, functions as a first line of defence against 
oxidative stress (Hardeland, 2005).  
 Several therapeutic agents and or antioxidants have been 
used to ameliorate the damaging effects of cyclophosphamide. 
Sakr et al. (2017) demonstrated the ameliorative effect of 
fennel oil in cyclophosphamide-induced toxicity of the kidney 
of rats. El-Naggar et al. (2015) reported the ameliorative 
effects of propolis against cyclophosphamide-induced toxicity 
of the kidney and liver of mice. The ameliorative effect of 
royal jelly on cyclophosphamide-induced prostatic damage in 
male rats has also been reported (Abdel-Hafez et al., 2017). 
With the exception of the report of Shokrzadeh et al. (2014) 
where graded doses of MLT were used during a seven-day 
duration to ameliorate cyclophosphamide-induced toxicity in 
the liver of mice, there is the paucity of research information 
on the role of MLT in cyclophosphamide-induced toxicity in 
rodents. This study was therefore designed to investigate the 
role of MLT in cyclophosphamide-induced toxicity of the 
liver and kidney of adult Wistar rats. 
 
MATERIALS AND METHODS 
 
Chemicals: CLP as well as MLT used for the study were 
purchased from Sigma-Aldrich Co, St Louis, Missouri, United 
States of America. All other reagents used in the study were 
of standard grade.  
 
Experimental Animals: All procedures used in the study 
were carried out according to the National Institutes of 
Health’s protocol on handling of laboratory animals for 
biomedical research (Garber et al. 2011). Twenty-four male 
Wistar rats (average weight of 190 g) obtained from the 
Experimental Animal Unit, Faculty of Veterinary Medicine, 
University of Ibadan, Nigeria, were used for the study.  The 
rats were kept in plastic cages under controlled environmental 
conditions, being kept on commercial rat pellets and clean 
water provided ad libitum. The rats used in the study were 
divided into four groups (n=6): 
• Group I (Control): Rats received 0.2 mL normal saline intra-
peritoneally for 14 days.  
• Group II (MLT): Rats received intra-peritoneal 10 mg/kg/day 
MLT for 14 days.  
• Group III (CLP): Rats received normal saline intra-peritoneally 
for 14 days followed by a single dose of CLP on the 15th day in 
a dose of 150 mg/kg intra-peritoneally.  
• Group IV (MLT + CLP): Rats received intraperitoneal 10 
mg/kg/day MLT for 14 days followed by a single dose of CLP 
150 mg/kg/day intraperitoneal at the 15th day. 
The dosage, duration and route of administration of MLT and 
CLP used in the study were as reported by Olukole et al. 
(2018), Abdel-Hafez et al. (2017), respectively. 
 
Sample Collection: 48-hours post-CLP administration, rats 
were weighed, anaesthetized under light diethyl ether; blood 
samples collected in plain tubes from each rat and 
centrifuged (centrifuge Jantezki, T30, Germany), at 5000 
rpm for 10 min for serum collection. Sera collected were 
separated and refrigerated at -20 °C until analysis. Liver and 
kidney samples were harvested and fixed in buffered neutral 
formalin and processed for histological analysis. 
 
Serum Biochemical Analysis: Serum Na+, K+, Cl- and HCO3- 
were determined by use of automated analyzers (Meyer and 
Harvey, 1988). Commercially available kits were used 
according to the respective manufacturer’s protocol for the 
measurement of serum liver function enzyme activity. As 
described by Ola-Davies et al. (2014), Serum alkaline 
phosphatase (ALP) activity was determined by a kit from 
BioSystems SA., Spain. Serum aspartate aminotransferase 
(AST), gamma glutamyltransferase (GGT), alanine 
transaminase (ALT), acid phosphatase and prostatic acid 
phosphatase activities, Urea, Creatinine, Total Bilirubin (TB), 
Conjugated Bilirubin (CB), Total Protein (TP) were measured 
using RANDOX® laboratory reagent kits obtained from 
RANDOX Laboratories Ltd., Ardmore, United Kingdom.  
 
Histopathology: Liver and kidney samples were collected in 
10% neutral buffered formalin for histological analysis. 
Tissues were processed and embedded in paraffin wax and 
sections were made of about 4-6 μm. After staining with 
haematoxylin and eosin, slides were examined under the 




Data were expressed as means ± SD. Means were compared 
using One-Way ANOVA. Statistical significance was 
considered at p< 0.05. Presentations of data in graphical 
formats were carried out with the aid of GraphPad Prism 5 





The effect of MLT on CLP-induced alterations in body, liver 
and kidney weights are given in figure 1 A-C. There was no 
significant decrease in body weight of CLP-treated rats 
compared to the control (figure 1A). Similarly, CLP induced 
reduction in kidney and liver weights compared to the control 
rats although the differences were not significant (figure 1B & 
C). Also, the pre-administration of MLT with CLP resulted in 
none significant increases in body as well as organ weights 
across the groups (figure 1A-C). 
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 Effect of melatonin on cyclophosphamide-induced changes 
in serum electrolytes of rats. 


































Means with different superscripts within rows are significantly 
different (P<0.05) 
 
The effects of MLT on the electrolytes of CLP-treated rats are 
given in Table 1. CLP significantly reduced the levels of Na+, 
K+ and Cl- compared to the control while the pre-treatment 
with MLT increased the levels of Na+, K+ and Cl-. However, 
there were no significant differences between the control and 
CLP groups for HCO3-. Cyclophosphamide induced 
significant decrease in the levels of serum proteins (albumin, 
globulin and total protein) compared to the control while the 
pre-treatment with MLT protected against these alterations 
(table 2). 
 With respect to liver function parameters, there were 
significant increases (p<0.05) in the levels of ALP, ALT, AST 
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Conversely, CLP did not induce any significant difference in 
the levels of CB compared to the control (figure 2E). 
However, the pre-treatment with MLT protected against the 
CLP-induced increases in ALP, ALT, AST and GGT levels. 
Kidney function tests revealed significant differences between 
the CLP-treated rats and the control for both serum creatinine 
and urea (Figure 3A-B). 
 The pre-treatment with MLT attenuated the observed 
elevations in serum creatinine and urea. Histologically, the 
control and MLT-treated rats revealed normal mono-nucleate 
and bi-nucleate hepatocytes in the liver parenchyma with 
normal central veins and sinusoids (Plate 1A and B). 
However, the CLP-treated rats had congested central veins 
and widened sinusoids (Plate 1C-E). The pre-administration 
of MLT with CLP attenuated these alterations in liver 
architecture (Plate 1F). 
 
Figure 1 
Effect of melatonin on CLP-induced alterations in 
body and organ weights. 







Plate 1.  
Photomicrographs showing the effect of melatonin on cyclophosphamide-induced changes in the liver of adult male rats  
A. Control rats showing normal central vein (CV), normal sinusoid(S), mono-nucleate (block arrow) and bi-nucleate (arrow) hepatocytes. 
 B. MLT treated rats showing normal hepatic plate, normal central vein (CV), normal sinusoid (S) and mono-nucleate hepatocyte (block 
arrow). 
C. CLP treated rats showing congested central vein (star).  
D. CLP treated rat showing widened sinusoids (WS).  
E. CLP treated rat showing congested central vein (star) and widened sinusoid (WS). 
F. MLT and CLP treated rat showing restored hepatic plate with normal sinusoid (S) and normal central vein (CV). 
 
 
Figure 3:  
Effect of melatonin on 
cyclophosphamide-induced alterations on 
kidney function parameters. 
Bars with different superscripts within 
rows are significantly different (P<0.05). 
 
Figure 2.  
Effect of MLT on CLP-induced 
alteration on liver function 
parameters. 
Bars with different superscripts 
within rows are significantly 
different (P<0.05) 
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Plate 2. 
Photomicrographs showing the effect of melatonin on cyclophosphamide-induced  changes in kidneys of adult male rats. 
A. Control group of rats showing normal glomerulus (G), normal proximal convoluted tubule (PCT), normal distal convoluted tubule (DCT). 
B. MLT treated rats showing normal renal corpuscles, normal glomerulus (G), normal loop of Henle (L). 
C. CLP treated rats showing congested loop of Henle (star), loss of glomerular epithelia and widened urinary space (arrow). 
D. CLP treated rats showing congested urinary spaces (star) 
E. CLP treated rats showing widened loop of Henle (WL). 
F. MLT and CLP treated rats showing restored renal corpuscles, glomerular epithelium (G), restored proximal convoluted tubules (PCT), 
restored distal convoluted tubules (DCT). 
 
Also, the kidneys of control and MLT-treated rats showed 
presence of basic kidney histology including glomerulus, 
proximal and distal convoluted tubules and loop of Henle 
(figure 5A and B). The CLP-treated rats showed presence of 
widened urinary and congested urinary spaces, congested loop 
of Henle and loss of glomerular epithelium (Plate 2C-E). 
However, these lesions were attenuated in the CLP+MLT 





This study has shown that cyclophosphamide, an established 
anticancer agent used for several malignancies is capable of 
inducing a number of alterations in renal and hepatic functions 
while the pre-treatment with melatonin, an antioxidant known 
to be synthesized by the mammalian pineal gland protected 
against these alterations. Our findings have further 
corroborated those of previous authors that CLP could cause 
damage to several tissues since it does not act specifically 
against cancerous cells but it acts on normal cells and tissues 
more efficiently, causing damage to them faster than 
cancerous cells (Bohnenstengel et al., 2000; Christina, 2008; 
Abdel-Hafez et al., 2017).  
 In the present study, CLP did not induce any significant 
differences in body and organ weights of the rats. This is in 
consonant with the reports of Selvakumar et al. (2005); Kanno 
et al. (2009); Adikwu and Bokolo (2018). However, a few 
authors have documented significant difference in body and 
organ weights due to treatment with CLP in rodents (Kanno et 
al., 2009; El-Naggar et al., 2015). These differences may be 
attributed to the duration and doses of CLP used by these 
authors. Kanno et al. (2009) and El-Naggar et al. (2015) used 
CLP doses as high as 250 and 200 mg/kg, respectively while 
the present study used 150 mg/kg. Also, while the present 
study administered rats with a single dose of 150 mg/kg of 
CLP, Kanno et al. (2009) treated mice with CLP doses as high 
as 250 mg/kg for 7 days. 
 Cyclophosphamide-treated rats demonstrated 
hyponatraemia suggestive of altered renal function resulting 
in reduced excretion of water. This is the direct effect of 
increased water reabsorption by the collecting ducts of the 
kidney. Similar findings have been documented in cancer 
patients undergoing cyclophosphamide therapy (Doshi et al., 
2012; Salahudeen et al., 2014). Also, the CLP induced 
hypokalaemia observed in this study might be as the result of 
potassium wasting nephropathy commonly encountered as a 
major side effect of use of cancer chemotherapeutic agents 
(Salahudeen et al., 2014; El-Naggar et al., 2015). The 
hypochloraemia observed in the CLP-treated rats may be 
traced to metabolic alkalosis. Hypokalaemia has been 
associated with metabolic alkalosis especially in the presence 
of kaliuresis, which occurs in response to low hydrogen ion 
concentration (Shajani-Yi et al., 2016).  
 The observed CLP-induced significant reductions in the 
level of serum proteins are suggestive of metabolic 
imbalances. Altered serum proteins are clinical indicators of 
toxicities as well as tools needed in the assessment of health 
status of humans and animals (Sacher and Mcpherson, 2000). 
In the present study, CLP induced significant increases in the 
levels of ALP, ALT, AST and GGT compared to the control. 
This is suggestive of alterations in liver function enzymes of 
the rats. The CLP-induced significant increases in the levels 
of AST, ALT and ALP have been documented by El-Nagger 
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et al. (2015) as well as Shokrzadeh et al. (2014). However, the 
pre-treatment with MLT attenuated the CLP-induced 
alterations in liver enzymes. This suggests that melatonin is 
hepatoprotective in CLP-induced liver toxicity. Similar 
findings on the effect of melatonin have been reported in mice 
exposed to CLP (Shokrzadeh et al.; 2014). Also, propolis, an 
antioxidizing agent, has also been reported to exert a 
protective effect against CLP-induced toxicity in the liver of 
rodents (El-Naggar et al., 2015).  
 The CLP-induced significant increase in serum creatinine 
and urea levels compared to the control rats is an indication of 
alterations in renal function. Similar findings were 
documented by El-Naggar et al. (2015) in mice exposed to 
single dose of 200 mg/kg of cyclophosphamide. Alterations in 
serum creatinine and urea levels have been associated with 
renal diseases especially in cases involving reduced 
glomerular filtration rate (McWilliam and Macnab, 2009). 
Interestingly, the pre-treatment with melatonin protected 
against the observed elevated serum creatinine and urea levels 
in the rats. This is similar to the report of Abdel-Hafez et al. 
(2017) on the role of melatonin in nephrotoxicity caused by 
the exposure of rats to anticancer agents. 
 The hepatic and renal lesions induced by the 
administration of CLP in rats used in the present study are 
consistent with our findings on the parameters of hepatic and 
renal functions. Inflammations as well as vascular congestion 
of the liver and kidney have been observed in toxicities due to 
administration of anticancer agents (Rather et al., 2016; 
Abdel-Hafez et al., 2017). Moreover, the loss of glomerular 
epithelium as well as the widened urinary space induced by 
CLP in the present study is suggestive of altered glomerular 
function.  The protective role of melatonin on the hepatic and 
renal lesions of rats treated with CLP is similar to that earlier 
reported by El-Naggar et al. (2015) and Abdel-Hafez et al. 
(2017) through the use of propolis and royal jelly, 
respectively. 
 Findings from alterations in electrolytes, serum proteins, 
renal and hepatic function parameters as well as 
histopathology have shown that CLP is capable of inducing 
hepatic and renal damage in rats while the pre-treatment with 
melatonin is able to protect against cyclophosphamide-
induced toxicity. Therefore, melatonin is recommended as a 
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